Statins May Accelerate Onset of Parkinson’s

Statins, which are widely used to lower cholesterol, may end up accelerating the onset of Parkinson’s disease in some patients.

Researchers at Penn State College of Medicine examined insurance claims data from 50 million people. They found 22,000 people that were diagnosed with Parkinson’s, though only 2,322 were newly diagnosed. They identified patients who were taking statins and determined how long they were taking the medication before Parkinson’s was diagnosed.

Patients that were on statins had a higher risk of developing Parkinson’s, the researchers reported in the journal Movement Disorders. Results also indicated that the association between statin use and Parkinson’s was strongest within the first 2.5 years a patient was on the drug. Researchers say that indicates that statins may facilitate the onset of Parkinson’s.

Prior research had suggested that statins might actually protect against Parkinson’s. One studyfound that people who stopped using statins were more likely to be diagnosed with the disease. But a different explanation for that finding has come to light.

“Use of statins may lead to new Parkinson’s disease-related symptoms, thus causing patients to stop using statins,” lead author Xuemei Huang, MD, said in a statement.

She cautioned that the results should not be interpreted as saying statins cause Parkinson’s. Instead, the findings indicate that statins serve no neuroprotective role. In addition, the data did not include people over the age of 65.

“If your mom has Parkinson’s disease and your grandmother has Parkinson’s disease, and you don’t have a family history of heart attacks or strokes, then you might want to ask your physician more questions to understand the reasons and risks of taking statins,” Huang said.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement